Ετικέτες

Πέμπτη 22 Μαρτίου 2018

Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies

Publication date: Available online 22 March 2018
Source:Cancer Cell
Author(s): Xiaojie Yu, H.T. Claude Chan, Christian M. Orr, Osman Dadas, Steven G. Booth, Lekh N. Dahal, Christine A. Penfold, Lyn O'Brien, C. Ian Mockridge, Ruth R. French, Patrick Duriez, Leon R. Douglas, Arwen R. Pearson, Mark S. Cragg, Ivo Tews, Martin J. Glennie, Ann L. White
Anti-CD40 monoclonal antibodies (mAbs) that promote or inhibit receptor function hold promise as therapeutics for cancer and autoimmunity. Rules governing their diverse range of functions, however, are lacking. Here we determined characteristics of nine hCD40 mAbs engaging epitopes throughout the CD40 extracellular region expressed as varying isotypes. All mAb formats were strong agonists when hyper-crosslinked; however, only those binding the membrane-distal cysteine-rich domain 1 (CRD1) retained agonistic activity with physiological Fc gamma receptor crosslinking or as human immunoglobulin G2 isotype; agonistic activity decreased as epitopes drew closer to the membrane. In addition, all CRD2-4 binding mAbs blocked CD40 ligand interaction and were potent antagonists. Thus, the membrane distal CRD1 provides a region of choice for selecting CD40 agonists while CRD2-4 provides antagonistic epitopes.

Graphical abstract

image

Teaser

CD40 agonist mAbs are being investigated for cancer treatment, whereas antagonistic mAbs are under investigation for the treatment of autoimmune and inflammatory conditions. Yu et al. show that the activity of a CD40 mAb is determined by an interplay between the location of its epitope within CD40 and its isotype.


http://ift.tt/2IMPPKD

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αναζήτηση αυτού του ιστολογίου